Tirzepatide weight loss averaged 15% to 21% of body weight over 72 weeks in the phase 3 SURMOUNT-1 trial of adults with obesity, the largest head-to-head weight-loss result of any FDA-approved medication. Sold as Zepbound for chronic weight management and Mounjaro for type 2 diabetes, tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist. The trial evidence, timeline, and side-effect picture are clear — here is what the data actually show.
What Tirzepatide Is and Why It Works for Weight
Tirzepatide is the first FDA-approved medication to activate both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Both are gut hormones released in response to food. Activating them slows how quickly the stomach empties, improves the insulin response to meals, lowers glucagon, and reduces appetite signaling in the brain.
The practical effect is that you feel fuller sooner, stay full longer, and experience less of the “food noise” that drives unplanned eating. The FDA approved the drug as Zepbound for chronic weight management in November 2023 in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus a weight-related condition.
How Much Weight Loss — SURMOUNT-1 Results
The pivotal SURMOUNT-1 trial enrolled 2,539 adults with obesity (without diabetes). Participants were randomized to tirzepatide 5, 10, or 15 mg weekly or placebo, on top of a reduced-calorie diet and physical activity counseling. Mean changes in body weight at week 72:
| Treatment | Mean Body-Weight Change | Proportion Losing ≥5% | Proportion Losing ≥20% |
|---|---|---|---|
| Placebo | -3.1% | 35% | 3% |
| Tirzepatide 5 mg | -15.0% | 85% | 30% |
| Tirzepatide 10 mg | -19.5% | 89% | 50% |
| Tirzepatide 15 mg | -20.9% | 91% | 57% |
These were published in the New England Journal of Medicine. For context, this is roughly 1.5 to 2 times the weight loss seen with semaglutide 2.4 mg (Wegovy) in STEP 1.
Timeline — What to Expect Week by Week
- Weeks 1-4 (2.5 mg titration): The 2.5 mg starter is a tolerance dose, not a therapeutic one. Small weight loss (1-3 lb) is common, mostly from decreased appetite.
- Weeks 5-16 (5 and 7.5 mg): Appetite suppression builds. Most people begin losing 1-2 lb per week.
- Weeks 17-40 (10 and 12.5 mg): The bulk of weight loss occurs during this window in trial data, with steady continued loss.
- Weeks 40-72+ (maintenance): Rate of loss slows; plateau is common. The body adapts to lower weight and energy expenditure.
Maintenance and Stopping
The SURMOUNT-4 trial tested what happens when tirzepatide is stopped after initial weight loss. Participants who switched from tirzepatide to placebo regained about 14% of body weight over the following year, while those who stayed on tirzepatide lost an additional 5.5%. The lesson is the same one seen with semaglutide and older weight-loss drugs: obesity is a chronic condition, and the drug manages — but does not cure — it. Clinical guidelines emphasize continued treatment when a medication is working and tolerated.
Side Effects During Weight Loss
Tirzepatide’s side effects are predominantly gastrointestinal:
- Nausea (about 29%), diarrhea (21%), constipation (17%), vomiting (13%), and abdominal pain (10%)
- Injection-site reactions, fatigue, and hair loss linked to rapid weight loss (~5%)
- Rare but serious: pancreatitis, gallbladder disease, acute kidney injury from dehydration, diabetic retinopathy progression, and hypoglycemia when combined with insulin or sulfonylureas
- Boxed warning for thyroid C-cell tumors based on rodent data; contraindicated in people with personal or family history of MTC or MEN 2
Most GI symptoms improve with slow titration, smaller meals, hydration, and avoiding high-fat foods early in treatment. Muscle preservation deserves special attention — rapid weight loss from any cause includes some lean-mass loss, so clinicians often recommend 1.0-1.2 g/kg target-body-weight protein intake plus resistance training.
Where Tirzepatide Fits
Tirzepatide for weight loss is for people who meet BMI and comorbidity criteria and cannot achieve or maintain clinically meaningful weight loss through lifestyle alone. For prediabetes, lifestyle change remains first-line and prediabetes is often reversible without medication. A structured nutrition plan paired with activity is the foundation of any weight-loss program, with or without pharmacotherapy.
The Bottom Line
Tirzepatide produces the largest average weight loss of any FDA-approved medication — roughly 15% at 5 mg and 21% at 15 mg over 72 weeks in SURMOUNT-1. Weight loss begins early and continues for about a year before slowing to a plateau, and regain is likely if the drug is stopped. Side effects are manageable with slow titration and lifestyle support, and serious risks are uncommon. Decisions about starting, adjusting, or stopping tirzepatide should be made with a qualified clinician.
This article is educational and does not replace personalized medical advice.
